1st Quarter - Report — BIOCOM for BIOCOM (2018)

Firm

BIOCOM

Client

BIOCOM

Income

—

Expenses

$50,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Hosted an advocacy fly-in about regenerative medicine Discussed how the life science community can help address the opioid crisis Supported expanded coverage of whole-genome sequencing Advocated for enhancements of the 340B drug program

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: Patent & Trademark Office (PTO); SENATE; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Advocated for increased funding for NIH and FDA in FY2018 omnibus.

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Natl Institutes of Health (NIH)

Taxation/Internal Revenue Code TAX

Advocated for the suspension of the medical device tax.

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: Food & Drug Administration (FDA); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE

Copyright/Patent/Trademark CPT

Advocated for reforms of IPR proceedings at the PTAB, including support of the STRONGER Patents Act

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.